CurrentBlue Cross Blue Shield - IowaPolicy 05.05.42

BENEFIT APPLICATION

Defines medical necessity criteria, required documentation, prescriber specialties, dosing/quantity limits, continuation criteria, and exclusions for coverage of Wegovy (semaglutide) for adults (and pediatric patients 6ge;12 for weight management) with obesity/overweight and established cardiovascular disease.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyBENEFIT APPLICATION

Policy CodePolicy 05.05.42

Change TypeRevised (Dec 2024)Reviewed (Jun 2025)

Effective DateDec 1, 2024

Next Review Date

Key ActionSubmit chart notes/medical records/claims history supporting existing CVD, BMI within 90 days, and documentation of concomitant guideline-directed medical therapies to initiate authorization review.

SourceLink

POLICY UPDATE CHANGES

Policy reviewed June 2025; revised December 2024 with current effective date December 1, 2024.

1Covered indication family (MACE reduction in CVD with overweight/obesity)

4Allowed prescriber specialties for initial requests

4Standard limit (pens) per 28 days

>=27BMI threshold (kg/m2)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Scope: Policy 05.05.42 defines medical necessity criteria, required documentation, prescriber specialty requirements, dosing/quantity limits, continuation criteria, and exclusions for coverage of Wegovy (semaglutide) for reduction of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease and obesity/overweight, and for weight management in pediatric patients aged 12 years and older when criteria are met. Coverage stance: mixed — the policy covers the FDA-approved cardiovascular and weight-management indications when all specified clinical and documentation criteria are met and denies coverage when criteria are not met. Key dates: Policy #: 05.05.42; Current effective date: 2024-12-01; Last review: 2025-06-01 (reviewed); Revised: December 2024. High-level permitted population: adults with established CVD and BMI >= 27 kg/m2 and pediatric patients aged >= 12 years for weight management per FDA labeling and policy criteria. Required documentation and administrative requirements include submission of chart notes/medical records/claims history for existing CVD, BMI within 90 days, documentation of concomitant guideline-directed therapies, and initial prescriber specialty restrictions for authorization review.

Clinical thresholds

ThresholdBMI >= 27 kg/m2

Ankle-Brachial Index (ABI)< 0.85 at rest (for symptomatic PAD)

Adherence fill-rate>= 80% (policy text documents '280% fill rate' which is interpreted as >= 80%)

Hemoglobin A1c (diabetes exclusion)< 6.5% (patient must NOT have diabetes defined as Hgb A1c >= 6.5%)

Coverage Criteria and Decision Logic

Initial Therapy - Major adverse cardiovascular event (MACE) reduction in established CVD with obesity/overweight

Covered when ALL of the following are met:

ALL of the following

Established CVD (any of the following)
- Prior myocardial infarction
- Prior stroke
- Symptomatic peripheral arterial disease as evidenced by one of the following: intermittent claudication with ankle-brachial index <0.85 at rest; peripheral arterial revascularization procedure; amputation due to atherosclerotic cardiovascular disease (ASCVD)
Body mass index (BMI) greater than or equal to 27 kg/m^2>= 27 kg/m^2
Absence of diabetes mellitus (Hemoglobin A1c < 6.5%)
Hgb A1c result must be provided
Receiving standard of care treatment for CVD including a drug from each of the following therapeutic classes (all required)
- Antiplatelet agent (e.g., aspirin, P2Y12 receptor blocker)
- Lipid-lowering agent (e.g., statin, ezetimibe, PCSK9 inhibitor)
- Antihypertensive agent (e.g., beta-blocker; ACE inhibitor or ARB)
Patient is participating in and will continue a weight loss regimen of a reduced calorie diet and increased physical activity
Documentation of counseling or program participation required
Patient will continue therapies for secondary prevention of cardiovascular disease in combination with the requested medication
No coadministration with another GLP-1 receptor agonist or semaglutide-containing product
Policy limitation: coadministration with other GLP-1s is not recommended
No history of pancreatitis within the prior 180 days
Chart notes or claims history must document absence of pancreatitis
Required documentation: chart notes, medical record documentation or claims history supporting established CVD; current (within 90 days) BMI documentation; documentation of concomitant guideline-directed therapies from required classes
Prescriber requirement (initial requests only): prescribed by or in consultation with a Cardiologist, Endocrinologist, Cardiometabolic specialist, or Lipid specialist

Alternate initial allowance

OR (allowed instead of meeting therapeutic-class requirements):

ANY of the following

Documented intolerance, contraindication, or inadequate response to the therapeutic classes required above (antiplatelet; lipid-lowering; antihypertensive)

Continuation of Therapy - MACE reduction in established CVD with obesity/overweight

Continued coverage when ALL of the following are met:

ALL of the following

Continued evidence of established CVD (any of the following)
- Prior myocardial infarction
- Prior stroke
- Symptomatic peripheral arterial disease as evidenced by intermittent claudication with ankle-brachial index <0.85 at rest; peripheral arterial revascularization procedure; or amputation due to ASCVD
Body mass index (BMI) greater than or equal to 27 kg/m^2>= 27 kg/m^2

Provider Actions and Authorization Requirements

Prior Authorization

Authorization review and documentation submission

Submit chart notes, medical records, or claims history to initiate authorization review showing: documentation of established cardiovascular disease (prior MI, prior stroke, or symptomatic PAD), current BMI measured within 90 days, and records supporting concomitant guideline-directed medical therapies.

Documentation Required

Prescriber specialty requirement (initial requests)

Initial requests must be prescribed by or in consultation with one of the following specialists: cardiologist, endocrinologist, cardiometabolic specialist, or lipid specialist.

Billing Rule

Quantity limits

Standard quantity limits apply: standard limit = 4 pens per 28 days for Wegovy auto-injector presentations. Approvals may also be subject to dosing limits in accordance with FDA-approved labeling and evidence-based guidelines.

Denial Risk

Not medically necessary if criteria not met

Claims will be considered not medically necessary and are subject to denial if the member does not meet the specified eligibility and clinical criteria outlined in the policy.

Documentation Required

Concomitant therapy requirement

Document that the patient is receiving standard-of-care treatments for CVD — including antiplatelet therapy, lipid-lowering therapy, and antihypertensive therapy — or provide documentation of intolerance, contraindication, or inadequate response to those medication classes.

Background, Evidence, and Definitions

Background: This policy aligns coverage with FDA-approved labeling for Wegovy (semaglutide) and with published clinical evidence, including the NEJM trial demonstrating semaglutide's cardiovascular outcomes in people with obesity without diabetes. The policy references the manufacturer labeling (Wegovy [package insert], Novo Nordisk, March 2024) and notes the FDA indication to reduce major adverse cardiovascular events in adults with established cardiovascular disease and overweight/obesity, and the separate FDA weight-management indication for adults and pediatric patients aged 12 years and older. The policy also states that coadministration with other semaglutide-containing products or any other GLP-1 receptor agonist is not recommended.

Source	Citation
Key clinical trial	Lincoff AM; Brown-Frandsen K; Colhoun HM; et al., Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes. N Engl J Med 2023;389:2221-2232.
Manufacturer labeling	Wegovy [package insert], Novo Nordisk, March 2024.

Definitions: Established cardiovascular disease (CVD): History of prior myocardial infarction, prior stroke, or symptomatic peripheral arterial disease, as evidenced by one of: intermittent claudication with ankle-brachial index < 0.85 at rest; peripheral arterial revascularization procedure; or amputation due to atherosclerotic cardiovascular disease (ASCVD).

OpenPayer

BENEFIT APPLICATION

Coverage Summary

Coverage Criteria and Decision Logic

Provider Actions and Authorization Requirements

Procedures and Billing Codes

Background, Evidence, and Definitions

Revision History